The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted ...

Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral ...

Background Current risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), ...

Edwards Lifesciences stock surged late Thursday after the medtech hiked its outlook following a key setback for rival Boston ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...

Edwards Lifesciences EW is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

MONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe ...